How do patients who fail first-line TB treatment but who are not placed on an MDR-TB regimen fare in South India?

Seven districts in Andhra Pradesh, South India. To a) determine treatment outcomes of patients who fail first line anti-TB treatment and are not placed on an multi-drug resistant TB (MDR-TB) regimen, and b) relate the treatment outcomes to culture and drug susceptibility patterns (C&DST). Retros...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:PloS one 2011-10, Vol.6 (10), p.e25698-e25698
Hauptverfasser: Burugina Nagaraja, Sharath, Satyanarayana, Srinath, Chadha, Sarabjit Singh, Kalemane, Santosha, Jaju, Jyoti, Achanta, Shanta, Reddy, Kishore, Potharaju, Vishnu, Shamrao, Srinivas Rao Motta, Dewan, Puneet, Rony, Zachariah, Tetali, Shailaja, Anchala, Raghupathi, Kannuri, Nanda Kishore, Harries, Anthony David, Singh, Sachdeva Kuldeep
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Seven districts in Andhra Pradesh, South India. To a) determine treatment outcomes of patients who fail first line anti-TB treatment and are not placed on an multi-drug resistant TB (MDR-TB) regimen, and b) relate the treatment outcomes to culture and drug susceptibility patterns (C&DST). Retrospective cohort study using routine programme data and Mycobacterium TB Culture C&DST between July 2008 and December 2009. There were 202 individuals given a re-treatment regimen and included in the study. Overall treatment outcomes were: 68 (34%) with treatment success, 84 (42%) failed, 36 (18%) died, 13 (6.5%) defaulted and 1 transferred out. Treatment success for category I and II failures was low at 37%. In those with positive cultures, 81 had pan-sensitive strains with 31 (38%) showing treatment success, while 61 had drug-resistance strains with 9 (15%) showing treatment success. In 58 patients with negative cultures, 28 (48%) showed treatment success. Treatment outcomes of patients who fail a first-line anti-TB treatment and who are not placed on an MDR-TB regimen are unacceptably poor. The worst outcomes are seen among category II failures and those with negative cultures or drug-resistance. There are important programmatic implications which need to be addressed.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0025698